Summary
Boston Scientific Corporation's (BSX) 2008 10-K filing reveals a challenging year marked by a significant net loss primarily driven by substantial goodwill and intangible asset impairment charges totaling $2.79 billion. This impairment was largely attributed to the impact of disruptions in the credit and equity markets following the 2006 Guidant acquisition. Despite the net loss, the company generated robust operating cash flow of $1.216 billion, demonstrating operational resilience. Net sales saw a slight decrease of 4% to $8.05 billion, impacted by increased competition in the drug-eluting stent market and the divestiture of non-strategic businesses. However, growth was observed in the Cardiac Rhythm Management (CRM) segment, up 8%, and Endosurgery, up 8%, highlighting strategic product launches and market penetration. The company is actively managing its financial position by reducing debt, having prepaid $1.425 billion under its term loan and credit facility in 2008. Furthermore, Boston Scientific is implementing cost-saving measures, including a plant network optimization plan aimed at simplifying manufacturing and improving gross margins. The company's product portfolio remains strong, with continued investment in innovation for both CRM and cardiovascular devices. Key risks highlighted include intense competition, regulatory scrutiny, and the ongoing impact of economic downturns on healthcare spending and reimbursement.
Financial Highlights
46 data points| Revenue | $8.05B |
| Cost of Revenue | $2.47B |
| Gross Profit | $5.58B |
| SG&A Expenses | $2.59B |
| Operating Expenses | $7.09B |
| Operating Income | -$1.50B |
| Interest Expense | $468.00M |
| Net Income | -$2.04B |
| EPS (Basic) | $-1.36 |
| EPS (Diluted) | $-1.36 |
| Shares Outstanding (Basic) | 1.50B |
| Shares Outstanding (Diluted) | 1.50B |
Key Highlights
- 1Reported a net loss of $2.036 billion ($1.36 per share) for 2008, largely due to $2.79 billion in goodwill and intangible asset impairment charges.
- 2Generated positive cash flow from operations of $1.216 billion, indicating operational strength.
- 3Net sales decreased by 4% to $8.05 billion, primarily impacted by competitive pressures in the drug-eluting stent market.
- 4Cardiac Rhythm Management (CRM) sales increased by 8% to $2.286 billion, driven by new product launches.
- 5Divested several non-strategic businesses in early 2008, generating approximately $1.3 billion in proceeds and streamlining operations.
- 6The company reduced its total debt by $1.444 billion during 2008, bringing total debt to $6.745 billion.
- 7Ongoing litigation with Johnson & Johnson resulted in significant legal charges, with a $334 million charge recorded in 2008 related to a patent infringement ruling.